

Synthesis of imidazo[1,2-a]pyridines by rearrangement of 2-pyridyl-3-arylaminoisoxazol-5-(2H)-ones

Jabbar Khalafy*, Ali Reza Molla Ebrahimlo, Ronak Eisavi, and Karim Akbari Dilmaghani

Department of Chemistry, Urmia University, Urmia 57159, Iran

E-mail: jKhalafi@yahoo.com; J.Khalafi@mail.urmia.ac.ir

Abstract


2-Pyridyl-3-arylaminoisoxazol-5(2H)-ones, substituted on N with a nitropyridine group **12a-12e** reacted with triethylamine in ethanol under reflux to give imidazo[1,2-a]pyridines **13a-13e** and carbon dioxide. An analogous synthesis failed to yield ethyl 3-(2-ethoxycarbonylphenyl) amino-5-oxo-2,5-dihydroisoxazole-4-carboxylate; the reaction of diethyl (2-ethoxycarbonylphenyl)thiocarbamoylmalonate with hydroxylamine gave the novel isoxazolo[3,2-b]quinazoline **14** by intramolecular acylation of the isoxazolone intermediate **14a**.

Keywords: Isoxazolones, 2-chloro-5-nitropyridine, rearrangements, triethylamine, imidazo-pyridines, isoxazoloquinazoline


Introduction

The reaction of 3-substituted isoxazolones with bases is not well known, and the only examples appear to be those reported by Doleschall¹, who alkylated the anion of ethyl 2,3-dimethyl-2,5-dihydro-5-oxo-isoxazole-4-carboxylate **1** in order to obtain γ -alkylated acetoacetates.


We have recently reported² that the reaction of 2-aryl-3-arylaminoisoxazolones **2** with triethylamine leads to the formation of indoles **3** and carbon dioxide, an outcome that is formally the same as that achieved by photolysis.³ The evidence for the indole structure, rather than that of an isomer, rested on the number of aryl proton signals visible in the ¹H-NMR spectrum.



We have recently reported² that the reaction of 2-aryl-3-phenylaminoisoxazolones **2** substituted on nitrogen with an isoquinoline or quinazoline group, react with triethylamine to give imidazo annelated compounds **4** and **5**, respectively. When the N-substituent is a nitropyridine the 2-aminoindole structure **6** was assigned to the product.



We have also reported⁴ that arylaminoisoxazol-5(2H)-one **7**, substituted on nitrogen with a benzothiazole group **8**, reacts with triethylamine in ethanol under reflux conditions to provide a convenient synthesis of ethyl 2-arylaminimidazo[2,1-b]benzothiazole-3-carboxylates **9**.




Prager and co-workers have reported⁵ that 2-aryl-3-aminoisoxazol-5(2H)-ones undergo solvolysis to form 1,3-dipoles that undergo intermolecular cyclisation to form either imidazopyridines or indoles in the presence of potassium carbonate. The mode of cyclisation is controlled by the electronegativity of the aryl substituent.

Here we report the synthesis of 2-pyridyl-3-arylaminisoxazol-5(2H)-ones **12a-12e**, where the N-substituent is a nitropyridine, and their reactions with triethylamine to form imidazopyridines **13a-13e**, respectively. We also report the formation of isoxazolo[3,2-b]quinazoline **14** by intramolecular acylation of the isoxazolone intermediate **14a**.

Results and Discussion

The required isoxazolones **12a-12e** were synthesised by N-arylation of the 2H-isoxazolones **11a-11e** which in turn were made by a modification of the procedure of Worrall.^{6,7} Thus, the reaction of the sodium salt of diethyl malonate in ethanol with aryl isothiocyanates gave the thiocarbamates **10a-10e** in good yield, and these were converted to the corresponding isoxazolones **11a-11e** by reaction with hydroxylamine (Scheme 1).




(a) Ar = 3-BrC₆H₄, (b) Ar = 3-MeC₆H₄, (c) Ar = 4-NO₂C₆H₄, (d), Ar = 3-(CO₂Et) C₆H₄,
(e) Ar = 4-(CO₂Et) C₆H₄

Scheme 1

N-Arylation of **11a-11e** with 2-chloro-5-nitropyridine then gave the desired starting materials **12a-12e** (Scheme I). While the formations of **12a-12e** appear trivial, the reaction generally proceeded best in the absence of solvent, by heating the required reagent under nitrogen at 130°C for an hour.

The rearrangement of 2-pyridyl-5-isoxazolones **12a-12e** proceeded in refluxing ethanol for 3-24h in the presence of triethylamine (Scheme 2).




(a) Ar = 3-BrC₆H₄, (b) Ar = 3-MeC₆H₄, (c) Ar = 4-NO₂C₆H₄, (d) Ar = 3-(CO₂Et) C₆H₄
(e) Ar = 4-(CO₂Et) C₆H₄

Scheme 2

Compound **12c** reacted more slowly, but gave the corresponding imidazopyridine in 72% yield. It has been reported⁵ that the rearrangement of **12c** in the presence of potassium carbonate in ethanol, returned mainly starting materials.

With a number of imidazopyridine structures in hand, the structures of all imidazopyridines were confirmed by ¹HNMR, ¹³CNMR, FT-IR, MASS spectra and microanalyses.

All compounds **13a-13e** showed H-7 to have *meta* coupling with H-5, but the resonance for H-5 could not be clearly observed in compounds **13a-13e**. The reason for the extreme broadening of this peak is unknown, though quadrupole coupling with N-4 is implicated. It has been reported previously⁸ that the X-ray structure of (**13**, Ar = Ph) did not show any unusual interactions. The reaction pathway resulting in the imidazopyridines is consistent with our earlier suggestion (Scheme 3).²




(13a) Ar = 3-BrC₆H₄, **(13b)** Ar = 3-MeC₆H₄, **(13c)** Ar = 4-NO₂C₆H₄, **(13d)** Ar = 3-(CO₂Et) C₆H₄
(13e) Ar = 4-(CO₂Et) C₆H₄

Scheme 3

Therefore, these base induced rearrangements appear to be generally applicable to the synthesis of imidazopyridines, which are suitable synthetic intermediates for a series of polycyclic heterocycles.

It is interesting that the reaction of **10f** with hydroxylamine gave ethyl 2,9-dioxo-4,9-dihydro-2*H*-isoxazolo[3,2-*b*]quinazoline **14** as white needles (81%), m.p. 266-268°C, by intramolecular acylation of the isoxazolonone intermediate **14a** (Scheme 4).



Scheme 4

The structure of **14** was confirmed by ¹HNMR, ¹³CNMR, FT-IR spectra and microanalysis.

Conclusions

The rearrangement of the 2-pyridyl-3-arylaminoisoxazolones substituted on nitrogen with nitropyridine (**12a-12e**) in the presence of triethylamine provides imidazo heterocycles (**13a-13e**) which are suitable synthetic intermediates for a series of new planar polycyclic heterocycles that could be expected to have pharmaceutical applications.^{9,10} In addition, the formation of the isoxazolo[3,2-b]quinazoline **14** opens up intriguing possibilities of carbenoid derived products of novel structure.

Experimental Section

General Procedures. Freshly distilled solvents were used throughout, and anhydrous solvents were dried according to Perrin and Armarego.¹¹ ¹H (400MHz) and ¹³C (75MHz) NMR measurements were recorded on a Bruker 400 spectrometer in deuteriochloroform with tetramethylsilane as internal standard, unless otherwise stated. Infrared spectra were recorded on a Thermo Nicolet (Nexus670) FT-infrared spectrometer, using sodium chloride cells, measured as Nujol mulls or films. Mass spectra were recorded on a Varian Matt 311 spectrometer and relative abundance of fragments is quoted in parentheses after the m/z values. Melting points were determined on a Philip Harris C4954718 apparatus and are uncorrected. Microanalyses were performed on a Carlo-Erba Analyzer 1104 at the University of Giessen, Germany.

Diethyl (3-bromophenyl)thiocarbamoylmalonate (10a). In a 100 mL round-bottomed flask, absolute ethanol (50mL) was reacted with sodium (2.9g, 0.126 mol) and, after cooling to room temperature, diethylmalonate (20g, 18.95 ml, 0.126 mol) was added. The reaction mixture was stirred at room temperature for 15 minutes; 3-bromophenyl isothiocyanate (26.96 g, 0.126 mol) was added and the stirring was continued for a further 6 h, during which time a yellow-white precipitate of sodium diethyl (3-bromophenyl)thiocarbamoylmalonate salt was formed. The salt was collected and washed with light petroleum ether (b.p. 30-60 °C) (3×50 mL) to give yellow crystals m.p.157-158 °C (34.22 g, 70 %). The pure salt was dissolved in water (40-50 mL) and neutralized with dropwise addition of HCl (10%) to maintain the pH at 7. The product was extracted with chloroform and the extract was washed with water (3x50 mL) and dried over anhydrous Na₂SO₄. Removal of solvent gave (**10a**) as a yellow oil (25.5g, 68%). ¹H NMR (CDCl₃) δ 1.29 (t, *J*= 7.1Hz, 3H), 4.27 (q, *J*= 7.1Hz, 2H), 5.06 (s, 1H), 7.22 (t, *J*= 8.06, 1H), 7.36 (bd, *J*= 7.95Hz, 1H), 8.67 (bd, *J*= 8.06Hz, 1H), 8.05 (t, *J*= 1.9Hz, 1H), 10.83 (bs, NH, 1H). FT-IR ν_{\max} 3296, 1747, 1590, 1541, 1476, 1394, 1168, 1023, 680, 784 cm⁻¹.

Diethyl (3-methylphenyl)thiocarbamoylmalonate (10b). This compound was prepared as described above, using 3-methylphenyl isothiocyanate (1.3 g, 8.7mmol) and stirring for a further 1h after addition of the isothiocyanate to diethylmalonate salt to give diethyl(3-methylphenyl)thiocarbamoyl malonate (1.924, 71%) as a pale yellow solid, m.p.53-54 °C. ¹H

NMR (CDCl₃) δ 1.33 (t, J = 7.2Hz, 6H), 2.38 (s, 3H), 4.29 (q, J = 7.2Hz, 2H), 4.30 (q, J = 7.2Hz, 2H), 5.09 (s, 1H), 7.09 (t, J = 7.8Hz, 1H), 7.55 (bs, 1H), 7.61(bd, J = 8Hz, 1H), 10.75 (s, exchanged by D₂O addition, NH, 1H). FT-IR ν_{\max} 3252, 1752, 1731, 1592, 1556, 1422, 1296, 1148, 1027, 858, 798, 717 cm⁻¹.

Diethyl (4-nitrophenyl)thiocarbamoylmalonate (10c). This compound was prepared as above, using 4-nitrophenylisothiocyanate (0.5g, 3.8mmol) and stirring for a further 1 h after addition of the isothiocyanate to diethylmalonate salt to give diethyl (3-methylphenyl)thiocarbamoylmalonate (1.1g, 97%) as a yellow solid, m.p.85-87°C (lit, 87-90 °C).⁵

Diethyl (3-ethoxycarbonylphenyl)thiocarbamoylmalonate (10d). This compound was prepared as described above, using 3-ethoxycarbonylphenyl isothiocyanate (26.08 g, 0.126 mol) and stirring for a further 1 h after addition of the isothiocyanate, giving diethyl (3-ethoxycarbonylphenyl) thiocarbamoylmalonate (41.6 g, 90%) as a yellow oil. ¹H NMR δ (ppm) 1.31 (t, J = 7.1Hz, 6H), 1.38 (t, J = 7.1Hz, 3H), 4.29 (q, J = 7.1Hz, 2H), 4.30 (q, J = 7.1Hz, 2H), 4.37 (q, J = 7.1 Hz, 2H), 5.1 (s, 1H), 7.48 (t, J = 7.9Hz, 1H), 7.92 (dt, J_1 = 7.8Hz, J_2 = 1.7Hz, 1H), 8.09 (dt, J_1 = 7.3Hz, J_2 = 1.2Hz, 1H), 8.33 (t, J = 1.6Hz, 1H), 10.90 (s, exchanged by D₂O addition, 1H, NH). ¹³C NMR δ (ppm) 13.39, 13.78, 60.74, 62.56, 66.74, 123.93, 127.22, 127.39, 128.40, 130.77, 138.22, 165.07, 165.16, 188.10. FT-IR ν_{\max} 3296, 2983, 1747, 1721, 1592, 1445, 1401, 1309, 1287, 1217, 1105, 1025, 758 cm⁻¹.

Diethyl (4-ethoxycarbonylphenyl)thiocarbamoylmalonate (10e). This compound was prepared as described above, using 4-ethoxycarbonylphenyl isothiocyanate (26.08 g, 0.126 mol) and stirring for a further 2 h after addition of the isothiocyanate, giving diethyl (4-ethoxycarbonylphenyl) thiocarbamoylmalonate (40.7g, 88%) as a yellow oil. ¹H NMR δ (ppm) 1.29 (t, J = 7.3Hz, 6H), 1.37 (t, J = 7.1Hz, 3H), 4.27 (q, J = 7.3Hz, 2H), 4.28 (q, J = 7.3Hz, 2H), 4.35 (q, J = 7.1 Hz, 2H), 5.08 (s, 1H), 7.96 (d, J = 8.7 Hz, 2H), 8.05 (d, J = 8.7 Hz, 2H), 11.02 (s, exchanged by D₂O addition, 1H, NH). ¹³C NMR δ (ppm) 13.33, 13.74, 60.47, 62.50, 67.02, 121.69, 127.75, 129.74, 141.85, 164.99, 165.04, 187.69. FT-IR ν_{\max} 3296, 2983, 1751, 1720, 1606, 1547, 1391, 1277, 1177, 1108, 1021, 857, 772 cm⁻¹.

Diethyl (2-ethoxycarbonylphenyl)thiocarbamoylmalonate (10f). This compound was prepared as described above, using 2-ethoxycarbonylphenyl isothiocyanate (26.08 g, 0.126 mol) and stirring for a further 2 h after addition of the isothiocyanate, giving diethyl (2-ethoxycarbonylphenyl) thiocarbamoylmalonate (43g, 93%) as a yellow oil. ¹H NMR (60 MHz, CDCl₃): δ (ppm) 1.21 (t, J = 7Hz, 3H), 1.35 (t, J = 7Hz, 6H), 4.12 (q, J = 7Hz, 4H), 4.24 (q, J = 7Hz, 2H), 4.93 (s, 1H), 6.94 (t, J = 7.5Hz, 1H), 7.25 (bt, J = 7Hz, 1H), 7.73 (bd, J = 7Hz, 1H), 8.76 (bd, J = 7.5Hz, 1H), 12.44 (bs, NH, 1H). FT-IR ν_{\max} 3252, 2982, 1735, 1678, 1620, 1529, 1488, 1451, 1402, 1388, 1302, 1267, 1200, 1096, 1023, 758 cm⁻¹.

Ethyl 3-(3-bromophenyl)amino-5-oxo-2,5-dihydroisoxazol-4-carboxylate (11a). To a solution of hydroxylamine hydrochloride (2g, 28.8 mmol) in water (8 mL), potassium bicarbonate (2.8 g, 28 mmol) was added slowly. Ethanol (32 mL) was added and the resulting potassium chloride was filtered off.

Diethyl (3-bromophenyl) thiocarbamoylmalonate (3.4 g, 9 mmol) was added to the filtrate and refluxed for 24h. The reaction mixture was acidified with dilute hydrochloric acid and the white precipitate was collected by vacuum filtration. The white solid was recrystallized from ethanol to give the desired product (2.51 g, 85%) as colourless crystals m.p. 100-102 °C. Anal. Calc for C₁₂H₁₁BrN₂O₄.H₂S: C, 41.73; H, 3.19; N, 8.11%; found: C, 41.87; H, 3.22; N, 8.18%. ¹H NMR (D₆-DMSO+CDCl₃) δ 1.38 (t, *J*= 7.1Hz, 3H), 4.37 (q, *J*= 7.1 Hz, 2H), 6.15 (bs, NH, 1H), 7.23 (dt, *J*₁= 8.2Hz, *J*₂= 1.8Hz, 1H), 7.28 (t, *J*= 7.8Hz, 1H), 7.33 (dt, *J*₁= 7.8Hz, *J*₂= 1.6Hz, 1H), 7.51 (t, *J*= 1.8Hz, 1H), 9.38 (bs, NH, 1H), ¹³C NMR(D₆-DMSO+CDCl₃) δ(ppm),14.49, 60.26, 75.21, 119.80, 122.92, 123.82, 128.24, 130.95, 137.58, 162.85, 165.37, 166.72. FT-IR *V*_{max} 3512, 3297, 1710, 1701, 1590, 1478, 1413, 1323, 1203, 1116, 1011, 794, 734 cm⁻¹; MS *m/z* (%) 328(M⁺,66%), 326(M⁺,68%), 282(81), 280(70), 201(26), 197(16), 171(26), 157(36), 91(31), 90(32), 76(21), 63(24), 45(19), 44(100), 40(47), 36(23) and HRMS *m/z* 325.99021 (C₁₂H₁₁BrN₂O₄ requires 325.99022).

Ethyl 3-(3-methylphenyl)amino-5-oxo-2,5-dihydroisoxazol-4-carboxylate (11b). The compound was prepared as described above using diethyl(3-methylphenyl) thiocarbamoylmalonate (1.1 g, 3.5 mmol) and refluxing for 24 h to give the desired product as colourless crystals (0.7 g, 75%), m.p.109-111 °C. ¹H NMR(D₆-DMSO+CDCl₃) δ 1.38 (t, *J*= 7.1Hz, 3H), 2.37 (s,3H), 4.35 (q, *J*= 7.1Hz, 2H), 7.02 (bd, *J*= 7.6Hz, 1H), 7.07 (bd, *J*= 7.9Hz, 1H), 7.1 (bs,1H), 7.27 (t, *J*= 7.8Hz, 1H), 9.31 (s, 1H, NH). ¹³C NMR (D₆-DMSO+CDCl₃) δ(ppm) 14.53, 21.34, 60.17, 74.82, 118.19, 121.82, 126.42, 129.47, 135.90, 139.75, 163.35, 165.64, 166.66. FT-IR *V*_{max} 3519, 3316, 1710, 1678, 1578, 1324, 1226, 1169, 1113, 1000, 795, 725 cm⁻¹.

Ethyl 3-(4-nitrophenyl)amino-5-oxo-2,5-dihydroisoxazol-4-carboxylate (11c). This compound was prepared as described above using diethyl (4-nitrophenyl)thiocarbamoylmalonate (1.1g, 3.23mmol) and refluxing for 24 hours to give the desired product (0.62g, 65%) as a yellow solid, m.p.158-160 °C (lit. 161-163 °C).⁵

¹H NMR (D₆-DMSO+CDCl₃) δ 1.30 (t, *J* = 7.1Hz, 3H), 4.36 (q, *J*= 7.1Hz, 2H), 6.32 (bs, NH, 1H), 7.51 (d, *J*= 9.1Hz, 2H), 8.23 (d, *J*= 9.1, 2H), 9.53 (s, NH, 1H). ¹³C NMR (D₆-DMSO+CDCl₃) δ 14.43, 60.37, 76.45, 118.82, 125.33, 142.68, 143.53, 161.35, 164.74, 168.48. FT-IR *V*_{max} 3470, 1755, 1723, 1681, 1632, 1582, 1518, 1498, 1418, 1345, 1211, 1117, 1021, 857, 790, 745 cm⁻¹.

Ethyl 3-(3-ethoxycarbonylphenyl)amino-5-oxo-2,5-dihydroisoxazole-4-carboxylate (11d). This compound was prepared as described above using diethyl (3-ethoxycarbonylphenyl) thiocarbamoylmalonate (12.48 g, 34 mmol) and refluxing for 48 hours to give the desired product (4.35g, 40%) as white needles, m.p. 185-187°C. Anal. Calc for C₁₅H₁₆ N₂O₆: C, 56.25; H, 5.00; N, 8.75%; found: C, 55.98; H, 4.93; N, 9.00%. ¹H NMR (D₆-DMSO) δ (ppm) 1.23(t, *J*= 7.05Hz, 3H), 1.32 (t, *J*= 7.1Hz, 3H), 4.15 (q, *J*= 7.05Hz, 2H), 4.31 (q, *J*= 7.1Hz, 2H), 4.40 (bs, exchanged by D₂O addition, 1H, NH), 7.44 (t, *J*= 7.9 Hz, 1H), 7.60 (bd, *J*= 7.7Hz, 1H), 7.63 (dt, *J*₁= 8.1Hz, *J*₂= 1.1Hz, 1H), 8.03 (bs, 1H), 9.06 (s, exchanged by D₂O addition, 1H, NH). ¹³C NMR (D₆-DMSO) δ (ppm) 14.18, 14.63, 58.31, 60.80, 72.09, 119.73, 122.77, 123.68, 129.41,

130.77, 139.45, 161.47, 164.90, 165.63, 169.20. FT-IR ν_{\max} 3403, 2986, 1697, 1694, 1611, 1555, 1492, 1455, 1369, 1293, 1216, 1111, 1087, 1026, 784, 747 cm^{-1} .

Ethyl 3-(4-ethoxycarbonylphenyl)amino-5-oxo-2,5-dihydroisoxazole-4-carboxylate (11e).

This compound was prepared as described above using diethyl (4-ethoxycarbonylphenyl) thiocarbamoylmalonate (12.48 g, 34 mmol) and refluxing for 24 hours to give the desired product (7.07g, 65%) as white needles, m.p. 126-129°C. Anal. Calc for $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_6$: C, 56.25; H, 5.00; N, 8.75%; found: C, 55.88; H, 4.92; N, 8.92%. ^1H NMR ($\text{CDCl}_3+\text{D}_6\text{-DMSO}$) δ (ppm) 1.38 (t, $J=7.1\text{Hz}$, 3H), 1.40 (t, $J=7.1\text{Hz}$, 3H), 4.35 (q, $J=7.1\text{Hz}$, 4H), 7.34 (d, $J=8.7\text{Hz}$, 2H), 7.55 (bs, exchanged by D_2O addition, 1H, NH), 8.04 (d, $J=8.7\text{Hz}$, 2H), 9.58 (s, exchanged by D_2O addition, 1H, NH). ^{13}C NMR ($\text{CDCl}_3+\text{D}_6\text{-DMSO}$) δ (ppm) 14.29, 14.47, 60.35, 60.98, 75.69, 119.39, 126.40, 131.13, 140.52, 162.49, 165.33, 165.62, 166.92. FT-IR ν_{\max} 3278, 2984, 2761, 1716, 1683, 1601, 1575, 1471, 1415, 1369, 1329, 1278, 1184, 1104, 1022, 798, 769 cm^{-1}

Ethyl 3-(3-bromophenyl)amino-2-(5-nitropyrid-2-yl)-5-oxo-2,5-dihydroisoxazol-4-carboxylate (12a).

A mixture of 2-chloro-5-nitropyridine (58mg, 0.367 mmol) and ethyl 3-(3-bromophenyl)amino-5-oxo-2,5-dihydroisoxazol-4-carboxylate (0.12g, 0.367mmol) was heated neat under an atmosphere of nitrogen in an oil bath at 130 °C for 1.5 h. The residue was recrystallized from ethanol to give the desired isoxazolone as yellow crystals (75mg, 46%), m.p.207-209°C. Anal. Calc for $\text{C}_{17}\text{H}_{13}\text{BrN}_4\text{O}_6$: C, 45.43, H, 2.89 N, 12.47%; found: C, 45.38; H, 2.57; N, 12.26%. ^1H NMR($\text{D}_6\text{-DMSO}+\text{CDCl}_3$) δ 1.14 (t, $J=7.1\text{Hz}$, 3H), 4.04 (q, $J=7.1\text{Hz}$, 2H), 7.20 (t, $J=2.9\text{Hz}$, 1H), 7.23 (dt, $J_1=8.0\text{Hz}$, $J_2=1.9\text{Hz}$, 1H), 7.29 (dt, $J_1=7.3\text{Hz}$, $J_2=1.9\text{Hz}$,1H), 7.45 (t, $J=1.9\text{Hz}$, 1H), 7.62 (d, $J=9.1\text{Hz}$, 1H), 8.69 (dd, $J_1=9.1\text{Hz}$, $J_2=2.7\text{Hz}$, 1H), 9.08 (d, $J=2.7\text{Hz}$, 1H), 10.72 (s, NH, 1H). ^{13}C NMR($\text{D}_6\text{-DMSO}+\text{CDCl}_3$) δ 13.99, 60.13, 78.89, 114.46, 121.27, 121.85, 125.85, 128.61, 130.33, 134.98, 139.29, 141.35, 143.60, 153.62, 158.82, 161.72,162.83. FT-IR ν_{\max} 3153, 1778, 1698, 1596, 1552, 1517, 1333, 1200, 1122, 969, 756 cm^{-1} ; MS $m/z(\%)$ 450(M^+ ,5%), 448(M^+ ,4%), 406(52), 405(13), 404(58), 279(55), 224(13), 157(13), 155(13), 78(13), 77(14), 44(100), 40(52) and HRMS 448.00184 ($\text{C}_{17}\text{H}_{13}\text{BrN}_4\text{O}_6$ requires 448.00185).

Ethyl (3-methyloxycarbonylphenyl)amino-2-(5-nitropyrid-2-yl)-5-oxo-2,5-dihydroisoxazol-4-carboxylate (12b).

This compound was prepared as described above using the corresponding isoxazolone (180mg, 0.69mmol) and 2-chloro-5-nitropyridine (109mg, 0.69mmol) to give the desired product as yellow needles (0.13g, 46%) after recrystallization from ethanol, m.p.160-163 °C. Anal. Calc for $\text{C}_{18}\text{H}_{16}\text{N}_4\text{O}_6$: C, 56.25, H, 4.16, N, 14.58%; found: C, 56.10; H, 3.86; N, 14.28%. ^1H NMR(CDCl_3) δ 1.26 (t, $J=7.1\text{Hz}$, 3H), 2.28(s, 3H), 4.22 (q, $J=7.1\text{Hz}$, 2H), 6.62-6.97 (m, 3H), 7.13 (t, $J=7.7\text{Hz}$, 1H), 7.54 (d, $J=9.1\text{Hz}$, 1H), 8.54 (dd, $J_1=9.1\text{Hz}$, $J_2=2.6\text{Hz}$,1H), 8.91 (d, $J=2.6\text{Hz}$,1H), 10.35 (s, NH,1H). ^{13}C NMR(CDCl_3) δ 14.25, 21.27, 60.98, 78.86, 114.82, 118.99, 122.64, 127.21, 129.14, 134.34, 137.41, 139.53, 141.45, 143.54, 153.87, 160.13, 163.15, 163.64. FT-IR ν_{\max} 3176, 1782, 1702, 1567, 1511, 1332, 1206, 1173, 1118, 968, 756 cm^{-1} ; MS $m/z(\%)$ 384(M^+ ,20%), 341(24), 340(100), 248(31), 230(28), 158(45), 107(20),91(70), 65(23), 44(84), 40(36) and HRMS 384.10698 ($\text{C}_{18}\text{H}_{16}\text{N}_4\text{O}_6$ requires 384.10699).

Ethyl 3-(4-nitrophenyl)amino-2-(5-nitropyrid-2-yl)-5-oxo-2,5-dihydroisoxazol-4-carboxylate (12c).

This compound was prepared as described for above using the corresponding isoxazolone (100mg, 0.34mmol) and 2-chloro-5-nitropyridine (63mg, 0.4 mmol) to give the desired product as cream solid (48.2mg, 35%) after recrystallization from ethanol, m.p.223-226°C (lit,225-228°C).⁵ Anal. Calc for C₁₇H₁₃N₅O₈: C, 49.15; H, 3.13; N, 16.86%; found: C,48.83; H,2.72; N,16.59. ¹HNMR(D₆-DMSO+CDCl₃) δ 1.17(t, *J*= 7.1Hz, 3H), 4.12 (q, *J*= 7.1Hz, 2H), 7.47 (d, *J*= 9.1Hz, 2H), 7.69 (d, *J*= 9.1Hz,1H), 8.14 (d, *J*= 9.1Hz, 2H), 8.71 (dd, *J*₁= 9.1Hz, *J*₂= 2.7Hz, 1H), 9.02 (d, *J*= 2.7Hz,1H), 10.93 (s, NH,1H). ¹³C NMR(D₆-DMSO+CDCl₃) δ 14.05, 60.21, 80.66, 114.44, 121.61, 124.45, 135.11, 141.52, 143.53, 143.87, 144.43, 153.34, 158.29, 161.61, 162.43. FT-IR ν_{\max} 3114, 1782, 1687, 1602, 1553, 1428, 1337, 1261, 1202, 1122,1082, 1011, 960, 858, 552 cm⁻¹; MS *m/z*(%) 415(M⁺,12%), 371(78), 369(11), 325(13), 300(11), 279(29), 189(18), 149(12), 70(11), 44(100). 40(38) and HRMS 415.07641 (C₁₇H₁₃N₅O₈ requires 415.07641).

Ethyl 3-(3-ethoxycarbonylphenyl)amino-2-(5-nitropyrid-2-yl)-5-oxo-2,5-dihydroisoxazole-4-carboxylate (12d).

This compound was prepared as described above using the corresponding isoxazolone (96 mg, 0.3 mmol) and 2-chloro-5-nitropyridine (48.5 mg, 0.3mmol) to give the desired product (60 mg, 45%) as cream needles, m.p. 193-195°C (decomposed). Anal. Calc for C₂₀H₁₈ N₄O₈: C, 54.29; H, 4.07; N, 12.67%; found: C, 54.08; H, 3.80; N, 13.00%. ¹H NMR δ (ppm) 1.26 (t, *J*= 7.1Hz, 3H), 1.39 (t, *J*= 7.1Hz, 3H), 4.23 (q, *J*= 7.1Hz, 2H), 4.36 (q, *J*= 7.1Hz, 2H), 7.33 (bs, 1H , 7.37 (t, *J*= 7.8Hz, 1H), 7.59 (d, *J*= 9.1Hz , 1H), 7.82 (bd, *J*= 7.0Hz, 2H), 8.57 (dd, *J*₁= 9.1Hz, *J*₂= 2.6Hz, 1H), 8.90 (d, *J*= 2.6Hz, 1H), 10.54 (s, exchanged by D₂O addition, 1H, NH). ¹³C NMR δ (ppm) 14.27, 14.28, 61.11, 61.50, 79.33, 114.58, 122.83, 125.93, 127.25, 129.40, 131.83, 134.60, 137.94, 141.47, 143.49, 153.71, 159.88, 162.82, 163.51, 165.35. FT-IR ν_{\max} 3371, 3107, 2958, 1782, 1712, 1692, 1567, 1532, 1451, 1421, 1337, 1285, 1204, 1118, 1028, 971, 859, 757 cm⁻¹.

Ethyl 3-(4-ethoxycarbonylphenyl)amino-2-(5-nitropyrid-2-yl)-5-oxo-2,5-dihydroisoxazole-4-carboxylate (12e).

This compound was prepared as described above using the corresponding isoxazolone (96 mg , 0.3 mmol) and 2-chloro-5-nitropyridine (48.5 mg, 0.3mmol) to give the desired product (63 mg, 48%) as white needles, m.p. 197-200°C. Anal. Calc for C₂₀H₁₈ N₄O₈: C, 54.29; H,4.07; N,12.67%; found: C,54.10; H,4.26; N,12.86%. ¹H NMR δ (ppm) 1.29 (t, *J*= 7.1Hz, 3H), 1.38 (t, *J*= 7.1Hz, 3H), 4.27 (q, *J*= 7.1Hz, 2H), 4.35 (q, *J*= 7.1Hz, 2H), 7.19 (d, *J*= 8.6 Hz, 2H), 7.59 (d, *J*= 9.1Hz, 1H), 7.96 (d, *J*= 8.6Hz, 2H), 8.58 (dd, *J*₁= 9.1Hz , *J*₂= 2.6Hz, 1H), 8.88 (d, *J*= 2.6Hz, 1H), 10.54 (s, exchanged by D₂O addition, 1H, NH). ¹³C NMR δ (ppm) 14.28, 29.72, 61.25, 61.28, 79.86, 114.53, 120.90, 127.95, 130.90, 134.62, 141.56, 141.65, 143.49, 153.68, 159.78, 162.64, 163.69, 165.44. FT IR ν_{\max} 3394, 3154, 2982, 1780, 1703, 1602, 1470, 1425, 1343, 1278, 1201, 1177, 1118, 1021, 859, 757 cm⁻¹.

Ethyl 2-(3-bromo phenyl)amino-6-nitroimidazo[1,2-a]pyridine-3-carboxylate (13a). The isoxazolone (**12a**) (65mg, 0.145mmol) and triethylamine (0.13 ml) were refluxed in ethanol (10ml) for 12h. The reaction mixture was left to cool to room temperature and the resulting precipitate was collected to give (**13a**) as yellow needles (35mg, 60%), m.p.161-163 °C . Anal. Calc for C₁₆H₁₃BrN₄O₄: C, 47.4, H, 3.2, N, 13.82%; found: C, 47.40; H, 2.85; N, 13.58%.

^1H NMR($\text{D}_6\text{-DMSO}+\text{CDCl}_3$) δ 1.55 (t, $J=7.1\text{Hz}$, 3H), 4.57 (q, $J=7.1\text{Hz}$, 2H), 7.18 (bdd, $J_1=8.0\text{Hz}$, $J_2=1.6\text{Hz}$, 1H), 7.22 (t, $J=7.8\text{Hz}$, 1H), 7.56 (dt, $J_1=7.4\text{Hz}$, $J_2=1.9\text{Hz}$, 1H), 7.58 (d, $J=9.6\text{Hz}$, 1H), 8.06 (bs, 1H), 8.18 (dd, $J_1=9.6\text{Hz}$, $J_2=2.1\text{Hz}$, 1H), 8.95(bs, 1H), 9.85(bs, 1H). ^{13}C NMR($\text{D}_6\text{-DMSO}+\text{CDCl}_3$) δ 14.63, 61.28, 99.23, 114.42, 116.64, 117.13, 116.06, 121.23, 122.55, 122.93, 125.59, 126.95, 130.40, 137.18, 140.72, 160.28. FT-IR ν_{max} 3306, 1664, 1590, 1561, 1457, 1407, 1342, 1308, 1212, 1134, 1106, 847, 763 cm^{-1} ; MS $m/z(\%)$ 406(M^+ , 89%), 404(M^+ , 86%), 279(100), 251(16), 233(14), 206(11), 184(12), 182(11), 102(12), 78(11), 77(11), 44(26), 40(50) and HRMS 404.01201 ($\text{C}_{16}\text{H}_{13}\text{BrN}_4\text{O}_4$ requires 404.01202).

Ethyl 2-(3-methylphenyl)amino-6-nitroimidazo[1,2-a] pyridine-3-carboxylate (13b). The isoxazolone (12b) (126mg, 0.37mmol) and triethylamine (0.13 ml) were refluxed in ethanol (10ml), for 3 hours. The reaction mixture was left to cool to room temperature and resulting precipitate was collected to give (13b) as a yellow solid (60mg, 54%), m.p.167-169 °C. Anal. Calc for $\text{C}_{17}\text{H}_{16}\text{N}_4\text{O}_4$: C, 60.00; H, 4.70; N, 16.47%; found: C, 59.58; H, 4.32; N, 16.00. ^1H NMR (CDCl_3) δ 1.54 (t, $J=7.1\text{Hz}$, 3H), 2.40 (s, 3H), 4.56 (q, $J=7.1\text{Hz}$, 2H), 6.90 (d, $J=7.4\text{Hz}$, 1H), 7.26 (t, $J=7.8\text{Hz}$, 1H), 7.50-7.55 (m, 3H), 8.15 (d, $J=9.7\text{Hz}$, 1H), 8.84 (bs, 1H), 9.94 (bs, 1H). ^{13}C NMR(CDCl_3) δ 14.59, 21.62, 61.05, 98.75, 113.94, 115.74, 119.20, 122.20, 123.98, 126.79, 129.01, 139.07, 139.22, 145.02, 146.84, 156.33, 167.64. FT-IR ν_{max} 3403, 1655, 1613, 1578, 1551, 1493, 1344, 1308, 1216, 958, 767 cm^{-1} ; MS $m/z(\%)$ 340(M^+ , 100%), 296(14), 294(40), 255(23), 248(30), 118(13), 91(25), 86(19), 44(11), 40(35) and HRMS 340.11715 ($\text{C}_{17}\text{H}_{16}\text{N}_4\text{O}_4$ requires 340.11716).

Ethyl 2-(4-nitrophenyl)amino-6-nitroimidazo[1,2-a] pyridine-3-carboxylate (13c). The isoxazolone (12c) (100mg, 0.24mmol) and triethylamine (0.13 ml) were refluxed in ethanol (10 ml) for 24 hours. The reaction mixture was left to cool to room temperature and the resulting precipitate was collected to give (13c) as a green solid (67mg, 72%), m.p.259-261 °C. Anal. Calc for $\text{C}_{16}\text{H}_{13}\text{N}_5\text{O}_6$: C, 51.75; H, 3.50; N, 18.86%; found: C, 51.33; H, 3.12; N, 18.63%. ^1H NMR ($\text{D}_6\text{-DMSO}+\text{CDCl}_3$) δ 1.44 (t, $J=7.1\text{Hz}$, 3H), 4.50 (q, $J=7.1\text{Hz}$, 2H), 7.83 (d, $J=9.7\text{Hz}$, 1H), 8.08 (d, $J=9.2\text{Hz}$, 2H), 8.25 (d, $J=9.2\text{Hz}$, 2H), 8.28 (dd, $J_1=9.7\text{Hz}$, $J_2=2.4\text{Hz}$, 1H), 9.30 (bs, NH, 1H), 10.02 (bd, $J=1.9\text{Hz}$, 1H). FT-IR ν_{max} 3381, 1664, 1609, 1575, 1509, 1475, 1317, 1273, 1209, 1102, 860, 749 cm^{-1} ; MS $m/z(\%)$ 371(M^+ , 100), 325(12), 280(9), 279(35), 251(11), 205(12), 76(9), 44(16), 40(23) and HRMS 371.08658 ($\text{C}_{16}\text{H}_{13}\text{N}_5\text{O}_6$ requires 371.08659).

Ethyl 2-(3-ethoxycarbonylphenyl)amino-6-nitroimidazo[1,2-a] pyridine-3-carboxylate (13d). The isoxazolone (12d) (106 mg, 0.24 mmol) and triethylamine (0.2mL) were refluxed in ethanol (10 ml) for 3hours. The reaction mixture was left to cool to room temperature and the resulting precipitate was collected to give (13d) (61 mg, 64%) as yellow needles, m.p. 172-174°C. Anal. Calc for $\text{C}_{19}\text{H}_{18}\text{N}_4\text{O}_6$: C, 58.28; H, 4.52; N, 14.07%; found: C, 58.54; H, 4.48; N, 14.45%. ^1H NMR δ (ppm) 1.43 (t, $J=7.1\text{Hz}$, 3H), 1.56 (t, $J=7.1\text{Hz}$, 3H), 4.41 (q, $J=7.1\text{Hz}$, 2H), 4.58 (q, $J=7.1\text{Hz}$, 2H), 7.45 (t, $J=7.9\text{Hz}$, 1H), 7.56 (d, $J=9.7\text{Hz}$, 1H), 7.74 (bd, $J=7.7\text{Hz}$, 1H), 8.09 (dd, $J_1=8.03\text{Hz}$, $J_2=1.3\text{Hz}$, 1H), 8.17 (dd, $J_1=9.7\text{Hz}$, $J_2=1.7\text{Hz}$, 1H), 8.26 (bs, 1H), 9.03 (bs, exchanged by D_2O addition, 1H, NH), 9.86 (bs, 1H). ^{13}C NMR δ (ppm) 14.36, 14.65, 61.16, 61.26, 99.14, 114.37, 119.67, 122.57, 122.83, 123.75, 126.97, 129.27, 131.50, 137.12, 139.62, 146.86, 166.40.

FT-IR ν_{\max} 3403, 3325, 2923, 1716, 1675, 1612, 1576, 1550, 1490, 1346, 1315, 1281, 1230, 1107, 750 cm^{-1} .

Ethyl 2-(4-ethoxycarbonylphenyl)amino-6-nitroimidazo[1,2-a] pyridine-3-carboxylate (13e).

The isoxazolone (12e) (106 mg, 0.24 mmol) and triethylamine (0.2mL) were refluxed in ethanol (10 ml) for 3 hours. The reaction mixture was left to cool to room temperature and the resulting precipitate was collected to give (13e) (67 mg, 70%) as bright yellow needles, m.p. 208-210°C. Anal. Calc for $\text{C}_{19}\text{H}_{18}\text{N}_4\text{O}_6$: C, 58.28; H,4.52; N,14.07%; found: C,58.01; H,4.33; N,14.27%. ^1H NMR δ (ppm) 1.40 (t, $J=7.1\text{Hz}$, 3H), 1.56 (t, $J=7.1\text{Hz}$, 3H), 4.37 (q, $J=7.1\text{Hz}$, 2H), 4.57 (q, $J=7.1\text{Hz}$, 2H), 7.57 (d, $J=9.6\text{Hz}$, 1H), 7.78 (d, $J=8.5\text{Hz}$, 2H), 8.03 (d, $J=8.5\text{Hz}$, 2H), 8.18 (dd, $J_1=9.6\text{Hz}$, $J_2=2.1\text{Hz}$, 1H), 9.17 (bs, exchanged by D_2O addition, 1H, NH), 9.84 (bs, 1H). ^{13}C NMR δ (ppm) 14.40, 14.60, 60.75, 61.41, 99.63, 114.55, 117.44, 122.60, 124.18, 126.98, 131.03, 137.26, 143.48, 146.59, 166.27. FT-IR ν_{\max} 3314, 2984, 1708, 1676, 1607, 1604, 1570, 1547, 1486, 1455, 1434, 1367, 1343, 1313, 1273, 1216, 1177, 1108, 1083, 1019, 857, 762, 750 cm^{-1} .

Ethyl 2,9-dioxo-4,9-dihydro-2H-isoxazolo[3,2-b]quinazoline-3-carboxylate (14).

To a solution of hydroxylamine hydrochloride (7.06g, 0.102mol) in water (30mL), sodium bicarbonate (10.17g, 0.102mol) was added slowly. Ethanol (80mL) was added and the resulting potassium chloride was filtered off. Diethyl (2-ethoxycarbonylphenyl)thiocarbamoylmalonate (12.48g, 34mmol) was added to the filtrate and the mixture was refluxed for 24 h. The reaction mixture was cooled to room temperature and acidified with 10% HCl. The white precipitate was collected and recrystallized from acetone to give the desired product (7.6g, 81%) as white needles, m.p. 266-268°C (decomposed). Anal. Calc for $\text{C}_{13}\text{H}_{10}\text{N}_2\text{O}_5$: C, 56.93; H, 3.64; N, 10.22%; found: C, 56.86; H, 3.48; N, 10.34%. ^1H NMR (D_6 -DMSO) δ (ppm) 1.30 (t, $J=7.1\text{Hz}$, 3H), 4.30 (q, $J=7.1\text{Hz}$, 2H), 7.45 (td, $J_1=7.6\text{Hz}$, $J_2=0.8\text{Hz}$, 1H), 7.85 (td, $J_1=7.8\text{Hz}$, $J_2=1.5\text{Hz}$, 1H), 8.0 (bd, $J=8.2\text{Hz}$, 1H), 8.11 (dd, $J_1=8.0\text{Hz}$, $J_2=1.3\text{Hz}$, 1H), 12.32 (bs, 1H, NH). ^{13}C -NMR (D_6 -DMSO) δ (ppm) 14.43, 59.82, 74.01, 116.07, 118.39, 125.02, 126.68, 135.24, 138.38, 150.27, 152.70, 161.32, 162.21. FT-IR ν_{\max} 3220, 2967, 1808, 1678, 1640, 1584, 1513, 1430, 1339, 1305, 1215, 1122, 1032, 929, 826, 790, 756, 681 cm^{-1} .

Acknowledgements

We are grateful to Prof R.H. Prager (Flinders University) for his valuable comments and Prof J. Ipaktschi (Giessen University) for determining the Microanalysis and Mass spectra.

References

1. Dolesschall, G.A. *Tetrahedron Lett.* **1988**, 29, 6339.
2. Khalafy, J.; Prager, R.H. *J.Sci.I.R.Iran.* **2000**, 11, 32.
3. Khalafy, J.; Prager, R.H. *J. Chem. Res(M).* **1999**, 518.

4. Khalafy, J.; Molla Ebrahimlo, A.R.; Akbari Dilmaghani, K. *J. Chin. Chem. Soc.* **2004**, *51*, 1347.
5. Jeffery, D.; Prager, R.H.; Turner, D.; Dreimanis, M. *Tetrahedron* **2002**, *58*, 9965.
6. Worrall, D.E. *J.Chem.Soc.* **1923**, *45*, 3092.
7. Worrall, D.E. *J.Chem.Soc.* **1918**, *40*, 415.
8. Jeffery, D.W.; Prager, R.H.; Taylor, M.R. *Acta Crystallogr.* **2001**, E57, 0980.
9. Tuteja, N. Pham, T.; Tuteja, R.; Ocham, A.; Falaschi, A. *Biochem. Biophys. Res. Commun.* **1997**, *236*, 636.
10. Stiborova, M.; Bicler, C.A.; Wiessler, M.; Frei, E. *Biochem. Pharmacol.* **2001**, *62*, 1675.
11. Perrin, D.D.; Armarego, W.L.F. *Purification of Laboratory Chemicals*; 3rd Edn. Pergamon Press: Oxford, U.K., 1988.